Early recognition of degenerative joint disease combined with a multimodal treatment approach that includes a comprehensive rehabilitation plan can improve patient outcomes.
How many of us have heard owners talk about their dog “slowing down”? “He’s just getting older,” they often say. Yet, according to Amber Ihrke, DVM, CCRT, CVA, CVSMT, CAC, CVPP, owner and medical director of Integrative Pet Care of Homer Glen in Homer Glen, Illinois, age alone does not cause pets to slow down. Instead, slowing down is a manifestation of underlying disease, and it is important to find the true cause and address it.
Commonly, the underlying cause is osteoarthritis (OA). OA affects 1 in 5 adult dogs and is the leading cause of chronic canine pain.1 It can lead to decreased quality of life, reduced performance and activity and, in some cases, eventual euthanasia. Ihrke told attendees at the American Veterinary Medical Association Virtual Convention that it is important to intervene before end-stage joint degeneration—preferably as soon as a patient’s activity level starts to decrease.
Pathophysiology and progression of OA
Ihrke first reviewed a bit about the pathophysiology and progression of OA.2 First, pathologic changes occur in the articular tissues, commonly manifested by thickened joint capsules. The synovial membrane then becomes inflamed, and the synovial fluid less viscous. Pain begins at this stage as a result of synovial inflammation, and it is during these early stages that intervening offers the most benefit. The next phase is cartilage deterioration. Finally, osteophytes develop and bone remodeling occurs. This mechanical failure of articular cartilage is the defining element of OA and is irreversible.
Stages of OA3
Stage 0: No risk factors, patient is clinically normal
Stage 1: At-risk dogs; clinical signs are difficult to detect, but physiologic factors of OA are present
Stage 2: Mild OA; clinical signs are intermittent and include obvious impairment of the ability to perform certain daily activities, consistent alterations in body carriage, and muscle loss
Stage 3: Moderate OA; patient has constant impairment of form and a diminished capacity to engage in activities of daily living
Stage 4: Severe disease; mobility is impaired, and the patient’s ability to move or jump is decreased compared with previous normal activity
Clinical disease caused by these pathophysiologic changes can be quantified using the Canine OsteoArthritis Staging Tool (COAST), which categorizes OA into 5 stages (see Stages of OA).3 Owners typically start noticing reduced activity in their pets during stage 2, and patients are presented for evaluation most commonly during stage 2 or 3.
Confirming the diagnosis
Before we can develop a treatment protocol, Ihrke said, we need to confirm the diagnosis. A thorough and systematic patient evaluation is important and should not be overlooked. This includes signalment (to help guide the differential diagnosis), a thorough history, gait assessment, physical examination, and diagnostic tests. The history should include detailed questions about the pet’s ability to perform various daily activities (eg, getting into and out of their bed, going up or downstairs, walking around the yard).
“It’s important to compare the pet’s current and past activity levels,” Ihrke said. “Knowing that a patient can walk 1 mile at the time of evaluation is a seemingly good sign, but it can be misleading if a couple months earlier the pet was able to walk 2 or 3 miles.” Additionally, be sure to establish whether the patient is a pet versus a performance animal.
When evaluating gait, do so in several situations, and from multiple directions, Ihrke advised. Assess the patient as they walk casually around the exam room and when moving on a leash at both a walk and a trot. Transitions from 1 position to another (eg, rising from lying down) can be telling, but these actions must be voluntary and without manual interference. Ihrke recommends using video recordings where possible and said use of a lameness scale is essential. “Many scales are available and will help objectively compare findings from 1 visit to the next, or assess accurately when evaluations are done by more than 1 associate,” she said. Importantly, the owner can conceptualize improvement more easily when they can see progress on a quantified scale.
The physical examination is clearly essential. The crepitus, range of motion, effusion, pain, instability (CREPI) system for joint evaluation provides a systematic approach.4 Palpate both sides of the patient, starting with the presumed unaffected areas. Assess muscle atrophy, joint swelling, asymmetry, muscle tenderness, and heat. The goal of the examination is to confirm the area of lameness and lead you toward a diagnostic plan. Much like a scoring system for gait is essential, a pain score is similarly important. The diagnostic plan would then include case-appropriate modalities, such as orthogonal radiographs and joint taps.
Managing OA
Ihrke presented a list of 5 management goals for dogs with OA:
Advertisement
Intervene early.
Improve quality of life.
Reduce pain.
Decrease flare-ups.
Increase daily activity.
These goals are best accomplished, she said, using a multimodal and comprehensive approach.
Medical management
One of the starting points of treatment is nonsteroidal anti-inflammatory drugs. Adjunctive therapies such as amantadine, amitriptyline, or gabapentin (or combinations thereof) may also be used. Disease-modifying agents such as polysulfated glycosaminoglycans may also be beneficial and are commonly used. Omega-3 fatty acid supplements, chondroprotective supplements, and diets rich in eicosapentaenoic acid are also beneficial.
Weight optimization
Ihrke sais this term is often better received by owners than “weight loss” or “diet,” and can have a great impact. Weight loss of 6.10% has been associated with a subjective decrease in lameness, and improvement on kinetic gait analysis can be seen with a weight loss of 8.85%.5 As such, her goal for patients is a standard 10% reduction in body weight, as weight optimization alone may help reduce clinical signs of OA.
Rehabilitation
Rehabilitation is part of the multimodal approach, but in itself is also multimodal. Environmental modifications to improve traction in the home (eg, carpet, yoga mats, booties) is 1 component. There are also many therapeutic aids, in addition to manual therapy. Thermotherapy employs a combination of cold packs (to reduce acute-phase inflammation) on affected joints, with hot packs (to increase blood flow, improve connective tissue extensibility, and promote muscle relaxation) on soft tissues in the surrounding regions. Other therapies include transcutaneous electrical nerve stimulation, which provides pain relief and can be used at home; photobiomodulation (therapeutic laser); hydrotherapy, which can reduce the load on hip joints by 60% when water is at hip level; therapeutic ultrasound; pulsed electromagnetic field therapy; and extracorporeal shockwave therapy. All of these modalities are used to reduce pain and inflammation or improve muscle relaxation and mobility. As such, some may be targeted to the affected joint and others on the adjacent muscle groups.
Manual therapy remains the most essential aspect of rehabilitation. “Above all other rehabilitation tools, manual therapy is always a component—and the cornerstone—of the treatment protocol,” Ihrke said. Manual therapy includes releasing trigger points, improving joint range of motion, and decreasing pain through massage.
The second most important aspect of the rehabilitation protocol is a therapeutic exercise program. “Fitness in dogs is not achieved via self-directed activities,” Ihrke said. “Walking around the yard is not the same as an intentional plan to target a specific group of muscles or a specific movement.”
Much like rehabilitation aids can be used to improve a patient’s pain control or function, intraarticular injections (eg, hyaluronic acid or corticosteroids) may do the same. These are administered on a case-by-case basis and are always prescribed alongside a corresponding rehabilitation plan. Further, intra-articular injections of platelet-rich plasma or stem cells may have a role in the future, particularly in early OA.
Setting SMART goals
All of these aspects of evaluation and treatment circle back to setting goals for the patient. The goals set by a clinician must take into account the goals of the owner and the role of the patient (whether it is a pet, working dog, or performance dog). If the owner’s goals are unrealistic, have a discussion to reach a reasonable consensus. Ihrke advised setting SMART goals with clients: specific, measurable, attainable, relevant, and time-based. An example of a SMART goal is to improve weight-bearing of the right pelvic limb by 15% (relevant, measurable, and specific) in 4 weeks (time-based and attainable).”
Summary
Ihrke’s comprehensive patient evaluation plan includes signalment, a thorough patient history, gait evaluation, physical examination, and diagnostic testing. A multimodal treatment protocol, including medications, weight optimization, supplements, and rehabilitation, is best implemented in the earliest stages of joint progression when possible. In this way, we can provide the most benefit to dogs suffering from OA that need our help to maintain a favorable quality of life.
Rebecca A. Packer, DVM, MS, DACVIM (Neurology/Neurosurgery), is an associate professor at Colorado State University College of Veterinary Medicine and Biomedical Sciences in Fort Collins. She is active in clinical and didactic training of veterinary students and residents and has developed a comparative neuro-oncology research program at Colorado State University.
References
1.Johnston SA. Osteoarthritis. Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract. 1997;27(4):699-723. doi:10.1016/s0195-5616(97)50076-3
2. Fox SM. Multimodal Management of Canine Osteoarthritis. CRC Press; 2017.
5.Marshall WG, Hazewinkel HA, Mullen D, De Meyer G, Baert K, Carmichael S. The effect of weight loss on lameness in obese dogs with osteoarthritis. Vet Res Commun. 2010;34(3):241-253. doi:10.1007/s11259-010-9348-7
Download Issue: dvm360 November 2020
